Technology

Flow cytometry and Advanced FASTinov Algorithms

FASTinov patented methodology is based on an early detection of microbial cell lesions or metabolic changes, relying on a proprietary combination of particular fluorescent probes that target specific changes and make these identifiable through flow cytometry. The technology has been optimized such that no flow cytometry knowledge is needed to perform FASTinov AST.

Advanced proprietary FASTinov computation then interprets the complex cytometry information and classifies bacterial cells in terms of their susceptibility phenotype in a growth independent manner.

“The FASTinov technology is truly disruptive. It has the potential to transform infection management and antibiotic policy globally.”

See the world’s fastest antibiogram in action

Fastest workflow for bloodstream bacterial infection

Ultra FAST AST workflows require AST to start as soon as blood cultures flag positive.

Once blood cultures flag positive, the semi-automated FASTinov AST can start. The sample preparation requires 10 min for any set of Blood Cultures, after which the lab technician is only intermittently required for few minutes.

The FASTinov AST report is generated within 2 hours, at any time of the day, because it does not require batch processing. There is no waiting for new positive blood cultures to finally start AST.

Discover our kits

Simulation of timeline: when do you get the antibiogram?



Blood culture

Time blood culture flags + :

FASTinov ultra-rapid AST

1st patient

8:00

10:00

2nd patient

8:00

10:30

3rd patient

9:00

11:00

4th patient

11:00

13:00

5th patient

14:00

16:00


Evidence / validation

FASTinov AST was validated with high categorical agreement compared to the reference method*, using more than 2,500 samples, with both the EUCAST and CLSI protocols.

Key results – EUCAST protocol

 

Categorial agreement

Very major errors

Reproducibility

FASTgrampos AST

97.8%

0.4%

99.4%

FASTgramneg AST

98.9%

0.9%

99.5%

FASTcolistin MIC

98.8%

1.2%

97.0%


Key results – CLSI protocol


Categorial agreement

Very major errors

Reproducibility

FASTgrampos AST

97.9%

0.3%

99.8%

FASTgramneg AST

97.9%

0.7%

99.3%

FASTcolistin MIC

94.9%

1.2%

97.0%


Detection of mechanisms of resistance

The FASTgramneg kit allows the detection of some mechanisms of resistance like ESBL presence, and the screening of AmpC and carbapenemases.



Sensitivity

Specificity

Accuracy

ESBL(EB group I)

95,7%

100%

99,3%

ESBL(EB group II)

100%

100%

100%

pAmpC

100%

100%

100%

Carbapenemases

92,2%

95,1%

94,1%

* IFU, data on file

Broad antibiotic panel

Because FASTinov’s technology is phenotypic and growth independent, an antibiogram is delivery in up to 2h regardless of the species and keeping state of the art accuracy. Validated for a broad combination of bacterial strains and 19 antibiotics:

  • Amikacin
  • Amoxacillin-clavulanic acid
  • Ampicillin
  • Cefepime
  • Cefotaxime
  • Cefoxitin
  • Ceftalozane-tazobactam
  • Ceftazidime
  • Ceftazidime-avibactam
  • Ciprofloxacin
  • Collistin
  • Gentamicin
  • Imipenem
  • Linezolid
  • Meropenem
  • Oxacillin
  • Penicillin
  • Piperacillin-tazobactam
  • Vancomycin

Publications

The FASTinov technology is the result of 9 years of cutting-edge research

Journal of Clinical Microbiology 4:JCM0054421

Clinical microbiology and infection, vol. 26,11 (2020): 1559.e1-1559.e4.

European Journal of Clinical Microbiology & Infectious Diseases, 39, 1907–1914.

Frontiers in Microbiology. 11:1944

International Journal of Antimicrobials Agents. Volume 54, Issue 6, December 2019, Pages 820-823

Single Cell Analysis. Singapore; Springer 155-169

Frontiers in Microbiology. Dec 12;8:2455

Antimicrob Agents Chemother. 2016 Mar 28. pii: AAC.02947-15.

26th ECCMID, Amsterdam, Netherlands, 2016.

25th ECCMID, Copenhagen, Denmark, 2015.

Clin Microbiol Infect. 2013 Jan;19(1):E8-E15.

Patents

  • Kit and method of detecting the resistant microorganisms to a therapeutic agent. WO/2012/164547 A1. Granted in Europe
  • Fluorescent method of detecting microorganisms resistant to a therapeutic agent. US14123757. Granted in USA. Same patent family granted in Japan, Brazil and India.
  • Improved therapeutic drug monitoring. Application No: EP 18737735.3. Granted in Europe.
  • FASTgramneg/FASTgrampos product patent application filled Feb 2022